Clinical use – Page 16 – Communicable Diseases Research

Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors

Article

Published on 2021-02-102022-10-30
Journal: Molecules [Category] COVID-19,

Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture

Brilacidin, 세포 배양에서 SARS-CoV-2 억제 입증

Article

Published on 2021-02-092022-09-10
Journal: Viruses [Category] MERS, 치료기술, 치료제,

[키워드] acute respiratory syndrome coronavirus AMPs antimicrobial peptide antimicrobial peptides Antiviral antiviral activity biological properties biological property brilacidin Calu Calu-3 captures causative agent Cell culture cell line Clinical use coronavirus coronavirus 2 coronavirus disease Coronavirus disease-19 COVID-19 COVID-19 disease Critical de novo death defensin demonstrated entry inhibition Evidence host defense human lung Increasing inhibit SARS-CoV-2 inhibition manuscript morbidity and mortality peptides peptidomimetic reduce referred to Remdesivir respiratory SARS-CoV-2 Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 small molecule strain synergistic therapeutic intervention therapeutic options These data treat Vero Viral viral entry virus
[DOI] 10.3390/v13020271 PMC 바로가기 [Article Type] Article

Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity

SARS-CoV-2에 대한 체액 면역 반응 및 중화 항체; 병인 및 보호 면역에 미치는 영향

Review

Published on 2021-01-292022-09-12
Journal: Biochemical and Biophysical Research Communication [Category] SARS, 진단,

[키워드] ACE2 Administered antibodies antibody approach B cells block viral entry cellular receptor characterized Clinical outcome Clinical use COVID-19 pathogenesis defined determine disease severity domain epitope glycoprotein Humoral response IgA IgM antibody immune response Immunity implication infected individual infected individuals information interact mAbs magnitude management monoclonal antibody natural infection neutralizing antibody occur other coronaviruses pandemic Pathogenesis PROTECT Protective protective immunity rapid response RBD Receptor binding domain Reinfection reported response SARS-CoV-2 Seroconversion the antibody the Spike therapy utility Vaccine Vaccines Viral protein virus Virus-specific IgG with COVID-19
[DOI] 10.1016/j.bbrc.2020.10.108 PMC 바로가기 [Article Type] Review

Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model

마우스 모델에서 SARS-CoV-2 스파이크 단백질에 의해 유도된 사이토카인 시그니처

Immunology

Published on 2021-01-282022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, 치료기술,

[키워드] acute respiratory distress acute respiratory distress syndrome Adenovirus alveolitis angiotensin Angiotensin-converting enzyme ARDS BALB/c mice BALF Bronchoalveolar lavage fluid change Clinical use colony-stimulating factor Combination contribute COVID-19 COVID-19 patient CSS cytokine Cytokine storm Cytokine storm syndrome Cytokines domain drugs effective enzyme Extracellular global health GM-CSF granulocyte granulocyte-macrophage colony-stimulating factor Health Human angiotensin-converting enzyme 2 IL-1α IL-6 IL-6 inhibitor immunostimulant indicated induced Inflammatory cytokines inhibitor inhibitors Injury interleukin interleukin 6 interleukin 6 (IL-6 investigated Jak lead lung Lung injury mAb mAbs magnetic resonance imaging mechanism Model monoclonal antibodies monoclonal antibody mortalities mouse murine model myeloperoxidase Neutralizing neutrophilic Occurrence opens phenotype polyinosinic-polycytidylic acid pro-inflammatory Protein reduced respiratory distress Respiratory distress syndrome resulting Safe SARS-CoV-2 signature spike syndrome the cytokine storm therapeutic TNF-α Tocilizumab Treatment wild-type
[DOI] 10.3389/fimmu.2020.621441 PMC 바로가기 [Article Type] Immunology

Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study

Article

Published on 2021-01-262022-10-31
Journal: Cancers [Category] COVID-19,

[키워드] 95% CI absolute lymphocyte acute respiratory syndrome adjusted odds ratio Biological caused Clinical outcome Clinical use Cohort contributed coronavirus coronavirus disease COVID-19 COVID-19 mortality COVID-19 patients current Factor granularity greater group Health identify initial intensity Intensive intensive care Intervention invasive ventilation Korean lymphopenia management Medical resources Mild-to-moderate Mortality mortality rate multivariable Oxygen requirements oxygen supply pandemic Patient patients with COVID-19 poor prognosis predict prediction Predictive prognostic Prognostic marker required resources rising SARS-CoV-2 severe disease course severity significantly significantly higher simple survival
[DOI] 10.3390/cancers13030471 PMC 바로가기 [Article Type] Article

The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial

Research Paper

Published on 2021-01-192022-10-04
Journal: EClinicalMedicine [Category] 임상, 치료법,

[키워드] 1:1 Administered Anosmia approved Barcelona calculated Clinical use Concentration conducted cough COVID-19 COVID-19 patients detectable disease disease onset dose doses double-blind early treatment Efficacy enrolled Enrollment evaluate Evidence Factor Fever finding Fisher funding global health headache humoral Hyposmia IgG titer in vitro inhibit Ivermectin ivermectin group malaise median age Nasopharyngeal swab no difference no risk occurred onset of fever Patient PCR PCR positive patient Placebo placebo-controlled placebo-controlled trial Primary outcome primary outcome measure proportion Randomized randomized clinical trial receive receiving recruited recruitment reduce reduction Registered replication of SARS-CoV-2 reported risk SARS-CoV-2 SARS-CoV-2 RNA severe disease single dose Support supported Symptom transmission of SARS-CoV-2 Treatment Trial trials Viral load
[DOI] 10.1016/j.eclinm.2020.100720 PMC 바로가기 [Article Type] Research Paper

Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment

Review

Published on 2021-01-142022-10-29
Journal: International Journal of Molecular Sciences [Category] COVID-19,

Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use

Research Article

Published on 2021-01-142022-10-28
Journal: PLoS ONE [Category] COVID-19,

Laboratory-Based Resources for COVID-19 Diagnostics: Traditional Tools and Novel Technologies. A Perspective of Personalized Medicine

Review

Published on 2021-01-132022-10-30
Journal: Journal of Personalized Medicine [Category] COVID-19,

[키워드] Accuracy antibody Asymptomatic carried category cause caused Clinical use Combination contagious Coronavirus infection COVID-19 COVID-19 in patients COVID-19 pandemic dependent on Diagnosis diagnostic diagnostics Efficiency Enzyme-linked immunosorbent assay (ELISA) Factors Final global healthcare healthcare Healthcare system identify increase increase in infected patient Infection isothermal amplification Laboratory lateral flow immunoassay Lateral flow immunoassay (LFIA) LFIA limitations Loop mediated isothermal amplification (LAMP) Medicine Mild novel pandemic patients patients with COVID-19 Personalized medicine platform polymerase chain population immunity promising biomarkers repeated Research resources retrospective reverse transcription Reverse transcription polymerase chain reaction (RT-PCR) RT-PCR SARS-CoV-2 SARS-CoV-2 virus Sensitivity and specificity serological severity Spread spread of COVID-19 susceptibility the disease the SARS-CoV-2 the timing Traditional Treatment Variation widespread with COVID-19
[DOI] 10.3390/jpm11010042 PMC 바로가기 [Article Type] Review

Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug

Article

Published on 2021-01-132022-10-28
Journal: Viruses [Category] COVID-19,